These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 31849089)

  • 1. Problems with paper entitled The impact of tacrolimus exposure on extrarenal adverse effects in adult transplant recipients.
    Jones TE
    Br J Clin Pharmacol; 2020 Dec; 86(12):2536-2537. PubMed ID: 31849089
    [No Abstract]   [Full Text] [Related]  

  • 2. The impact of tacrolimus exposure on extrarenal adverse effects in adult renal transplant recipients.
    Campagne O; Mager DE; Brazeau D; Venuto RC; Tornatore KM
    Br J Clin Pharmacol; 2019 Mar; 85(3):516-529. PubMed ID: 30414331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of a Clinical Solid Organ Transplant Pharmacist on Tacrolimus Nephrotoxicity, Therapeutic Drug Monitoring, and Institutional Revenue Generation in Adult Kidney Transplant Recipients.
    Griffin SP; Nelson JE
    Prog Transplant; 2016 Dec; 26(4):314-321. PubMed ID: 27628498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in the commercial brand of tacrolimus lead to subtherapeutic trough levels and acute rejection in renal transplant recipients.
    Arreola-Guerra JM; Alberú J; Chew-Wong A; Macias DM; Hernández-Rosales J; Zuñiga-Macías L; Delgadillo-Castañeda R; Ricalde-Ríos G; Haro-Alcalde F; Villafán-Bernal JR; Ramos-Medellín CL; Reyes-Acevedo R
    Clin Transplant; 2019 Dec; 33(12):e13749. PubMed ID: 31691354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nationwide conversion to generic tacrolimus in pediatric kidney transplant recipients.
    Naicker D; Reed PW; Ronaldson J; Kara T; Wong W; Prestidge C
    Pediatr Nephrol; 2017 Nov; 32(11):2125-2131. PubMed ID: 28660366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-2 receptor antibody does not reduce rejection risk in low immunological risk or tacrolimus-treated intermediate immunological risk renal transplant recipients.
    Lim WH; Chadban SJ; Campbell S; Dent H; Russ GR; McDonald SP
    Nephrology (Carlton); 2010 Apr; 15(3):368-76. PubMed ID: 20470309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New-Onset Diabetes After Transplantation: Comparison Between a Cyclosporine-Based and a Tacrolimus-Based Immunosuppressive Regimen.
    Zolota A; Miserlis G; Solonaki F; Tranda A; Antoniadis N; Imvrios G; Fouzas I
    Transplant Proc; 2018 Dec; 50(10):3386-3391. PubMed ID: 30577210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermoid cysts in kidney transplant patients receiving tacrolimus.
    Verma S; Batra R; Gupta S; Zouboulis CC
    Dermatol Ther; 2020 Mar; 33(2):e13259. PubMed ID: 32043723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Why dose adjust systemic exposure when looking for associations with adverse events in tacrolimus-treated transplant recipients?
    Robertsen I; Woillard JB; Åsberg A
    Br J Clin Pharmacol; 2020 Dec; 86(12):2535. PubMed ID: 31144343
    [No Abstract]   [Full Text] [Related]  

  • 11. Immune monitoring with a lymphocyte adenosine triphosphate assay in kidney transplant recipients treated with a calcineurin inhibitor.
    Sugiyama K; Tsukaguchi M; Toyama A; Satoh H; Saito K; Nakagawa Y; Takahashi K; Tanaka S; Onda K; Hirano T
    Exp Clin Transplant; 2014 Jun; 12(3):195-9. PubMed ID: 24907718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delayed Initiation of Tacrolimus Is Safe and Effective in Renal Transplant Recipients With Delayed and Slow Graft Function.
    Liu Y; Liu H; Shen Y; Chen Y; Cheng Y
    Transplant Proc; 2018 Oct; 50(8):2368-2370. PubMed ID: 30316359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative analysis for optimizing the modified release tacrolimus (Advagraf) after kidney transplantation: A prospective randomized trial.
    Bakr MA; Nagib AM; Donia AF; Denewar AA; Abu-Elmagd MM; Abbas MH; Abdel-Rahman AM; Mashaly ME; Elsaftawy MM; Ghoneim MA
    Saudi J Kidney Dis Transpl; 2018; 29(6):1267-1273. PubMed ID: 30588956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New-onset diabetes after transplantation--should it be a factor in choosing an immunosuppressant regimen for kidney transplant recipients.
    Chadban S
    Nephrol Dial Transplant; 2008 Jun; 23(6):1816-8. PubMed ID: 18326882
    [No Abstract]   [Full Text] [Related]  

  • 15. Tacrolimus-associated gastrointestinal ulcers in a kidney transplant recipient.
    Forcey DS; Clayton-Chubb D; Gurry G; Bhatt S; Wilson S; Teh P; Morrissey O; Roberts S; Basu G
    Intern Med J; 2023 Jun; 53(6):1087-1088. PubMed ID: 37349275
    [No Abstract]   [Full Text] [Related]  

  • 16. A 12-month single arm pilot study to evaluate the efficacy and safety of sirolimus in combination with tacrolimus in kidney transplant recipients at high immunologic risk.
    Lee J; Lee JJ; Kim BS; Lee JG; Huh KH; Park Y; Kim YS
    J Korean Med Sci; 2015 Jun; 30(6):682-7. PubMed ID: 26028917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New formulations of tacrolimus and prevention of acute and chronic rejections in adult kidney-transplant recipients.
    Jouve T; Rostaing L; Malvezzi P
    Expert Opin Drug Saf; 2017 Jul; 16(7):845-855. PubMed ID: 28494654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Effectiveness of Once-Daily, Prolonged-Release Tacrolimus in De Novo Kidney Transplant Recipients: 5-year, Multicenter Postmarketing Surveillance in Japan.
    Wakasugi N; Uchida H; Uno S
    Transplant Proc; 2018 Dec; 50(10):3296-3305. PubMed ID: 30577199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validity and reliability of a novel immunosuppressive adverse effects scoring system in renal transplant recipients.
    Meaney CJ; Arabi Z; Venuto RC; Consiglio JD; Wilding GE; Tornatore KM
    BMC Nephrol; 2014 Jun; 15():88. PubMed ID: 24925208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Late conversion from tacrolimus to a belatacept-based immuno-suppression regime in kidney transplant recipients improves renal function, acid-base derangement and mineral-bone metabolism.
    Schulte K; Vollmer C; Klasen V; Bräsen JH; Püchel J; Borzikowsky C; Kunzendorf U; Feldkamp T
    J Nephrol; 2017 Aug; 30(4):607-615. PubMed ID: 28540602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.